Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a promising investment option due to their impressive targeted drug discovery platform, as well as their strong pipeline of potential treatments for precision oncology and genetic diseases. Their recent financing and increased possibilities of FDA approval for their lead drug, zovegalisib, also provide positive indications for future success. Despite the inherent risks in drug development and potential competition, Relay Therapeutics has shown strong efficacy and safety results in clinical trials, increasing their chances of success in the market.

Bears say

Relay Therapeutics is a clinical-stage precision medicine company that focuses on developing therapies for precision oncology and genetic diseases. Despite promising early data for its drug, zovegalisib, analysts are concerned about the company's financials, including the high costs of systemic therapies and potential competition from other companies. Additionally, the limited efficacy data and small sample size may make it difficult for Relay to gain regulatory approval, leading to a negative outlook on the stock.

RLAY has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 9 analysts, RLAY has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.